<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418467</url>
  </required_header>
  <id_info>
    <org_study_id>EMPATHY-1</org_study_id>
    <nct_id>NCT03418467</nct_id>
  </id_info>
  <brief_title>Risk Factors in Tachycardiomyopathy</brief_title>
  <acronym>EMPATHY</acronym>
  <official_title>Evaluation of Risk Factors for Therapeutic Outcome in Patients With Tachycardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decision between rate control and rhythm control can be a challenge in clinical practice.
      While there is some guiding evidence, we still lack a comprehensive insight into different
      subgroups of patients that will benefit from a rhythm control treatment.

      EMPATHY is a prospective clinical study in patients presenting with heart failure and a
      tachyarrhythmic rhythm disturbance. Biomarkers, routinely obtained results from clinical
      examinations, and results from endomyocardial biopsies shall be evaluated to identify
      patients which have better outcome from a rhythm control strategy by ablation therapy or, if
      contraindicated by pharmacological rhythm control.

      This study is designed to identifying risk factors and subgroups profiting from rhythm
      restoration and therefore improve current therapeutic approaches and the rate of
      recurrence-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>histological characteristics</measure>
    <time_frame>3 months</time_frame>
    <description>Identification of histopathological criteria, which indicate better outcome after rhythm control. Recovery of left ventricular ejection fraction (assessed by echocardiography) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence of rhythm disturbance</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the recurrence of the underlying rhythm disturbance (ECG, 7 day holter monitoring, implantable event recorder)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the rate of unplanned rehospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class (New York Heart Association)</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the extend of heart failure symptoms.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Ventricular Premature Complexes</condition>
  <arm_group>
    <arm_group_label>tachycardiomyopathy</arm_group_label>
    <description>Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dilated cardiomyopathy</arm_group_label>
    <description>Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting at the University Hospital Tübingen with decreased left ventricular
        ejection fraction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed left ventricular ejection fraction ≤ 50%

          -  endomyocardial biopsy available

          -  tachycardic rhythm disturbance with a rhythm control strategy planned for tachycardic
             atrial fibrillation or flutter (≥100/min) or more than 10000 ventricular premature
             beats in 24 hours

        Exclusion Criteria:

          -  age &lt;18 years

          -  patient unable or unwilling to give informed consent

          -  coronary artery stenosis &gt;50%

          -  relevant valvular disease

          -  simultaneous contraindications against amiodarone treatment and pulmonary vein
             isolation/ablation therapy

          -  present or suspected alcohol/drug dependency will result in exclusion from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Seizer, MD</last_name>
    <phone>0049 7071 29 83688</phone>
    <email>peter.seizer@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Heinzmann, MD</last_name>
    <phone>0049 7071 29 83688</phone>
    <email>david.heinzmann@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik III (Kardiologie)</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Seizer, MD</last_name>
      <phone>0049 7071 29 83688</phone>
      <email>peter.seizer@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>David Heinzmann, MD</last_name>
      <phone>0049 7071 29 83688</phone>
      <email>david.heinzmann@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tachycardiomyopathy</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>EMID (enrichment of mitochondria at the intercalated discs)</keyword>
  <keyword>Biopsy</keyword>
  <keyword>empathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

